Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol

László Váróczy, E. Zilahi, Ágnes Gyetvai, Béla Kajtár, L. Gergely, S. Sipka, A. Illés

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The addition of rituximab to conventional chemotherapy has significantly improved the treatment outcome in diffuse large B-cell lymphoma. However, differences in treatment response and survival data can be observed independently from the International Prognostic Index scores. The current study evaluated the impact of Fc-gamma-receptor IIIa polymorphism and gene expression profile on the response of DLBCL patients to R-CHOP therapy as well as on their survival results. Fifty-one patients were involved, thirty-two females, nineteen males, their median age was 53.1 years. The FCGR3A polymorphism at the 158. amino acid position determined with PCR method showed the following results: VV: 12 cases (23.5%), VF: 29 cases (56.8%) and FF: 10 cases (19.6%), respectively. There was no significant difference between the treatment responses of the three groups. The event-free survival data were less favorable in the F-allele carriers than in V/V homozygous patients, but without any significancy, and the overall survival curves were almost the same. As for the gene expression profile, 20 patients' biopsy specimens showed germinal center and 31 showed non-germinal center characteristics. Treatment results did not differ from each other in the two groups. Both the event-free and the overall survival data were more favorable in the GC group, however the differences were not significant. Our results contest the predictive value of Fc-gamma-receptor IIIa polymorphism and gene expression profile in diffuse large B-cell lymphoma.

Original languageEnglish
Pages (from-to)43-48
Number of pages6
JournalPathology and Oncology Research
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

IgG Receptors
Lymphoma, Large B-Cell, Diffuse
Transcriptome
Disease-Free Survival
Survival
Germinal Center
Therapeutics
Alleles
Biopsy
Amino Acids
Drug Therapy
Polymerase Chain Reaction
R-CHOP protocol

Keywords

  • Diffuse large B-cell lymphoma
  • Fc-gamma-receptor IIIa polymorphism
  • Gene expression profile
  • Rituximab
  • Survival
  • Treatment response

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

@article{7f842f9bd7514bcdb30a85ddfa413775,
title = "Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol",
abstract = "The addition of rituximab to conventional chemotherapy has significantly improved the treatment outcome in diffuse large B-cell lymphoma. However, differences in treatment response and survival data can be observed independently from the International Prognostic Index scores. The current study evaluated the impact of Fc-gamma-receptor IIIa polymorphism and gene expression profile on the response of DLBCL patients to R-CHOP therapy as well as on their survival results. Fifty-one patients were involved, thirty-two females, nineteen males, their median age was 53.1 years. The FCGR3A polymorphism at the 158. amino acid position determined with PCR method showed the following results: VV: 12 cases (23.5{\%}), VF: 29 cases (56.8{\%}) and FF: 10 cases (19.6{\%}), respectively. There was no significant difference between the treatment responses of the three groups. The event-free survival data were less favorable in the F-allele carriers than in V/V homozygous patients, but without any significancy, and the overall survival curves were almost the same. As for the gene expression profile, 20 patients' biopsy specimens showed germinal center and 31 showed non-germinal center characteristics. Treatment results did not differ from each other in the two groups. Both the event-free and the overall survival data were more favorable in the GC group, however the differences were not significant. Our results contest the predictive value of Fc-gamma-receptor IIIa polymorphism and gene expression profile in diffuse large B-cell lymphoma.",
keywords = "Diffuse large B-cell lymphoma, Fc-gamma-receptor IIIa polymorphism, Gene expression profile, Rituximab, Survival, Treatment response",
author = "L{\'a}szl{\'o} V{\'a}r{\'o}czy and E. Zilahi and {\'A}gnes Gyetvai and B{\'e}la Kajt{\'a}r and L. Gergely and S. Sipka and A. Ill{\'e}s",
year = "2012",
month = "1",
doi = "10.1007/s12253-011-9414-7",
language = "English",
volume = "18",
pages = "43--48",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol

AU - Váróczy, László

AU - Zilahi, E.

AU - Gyetvai, Ágnes

AU - Kajtár, Béla

AU - Gergely, L.

AU - Sipka, S.

AU - Illés, A.

PY - 2012/1

Y1 - 2012/1

N2 - The addition of rituximab to conventional chemotherapy has significantly improved the treatment outcome in diffuse large B-cell lymphoma. However, differences in treatment response and survival data can be observed independently from the International Prognostic Index scores. The current study evaluated the impact of Fc-gamma-receptor IIIa polymorphism and gene expression profile on the response of DLBCL patients to R-CHOP therapy as well as on their survival results. Fifty-one patients were involved, thirty-two females, nineteen males, their median age was 53.1 years. The FCGR3A polymorphism at the 158. amino acid position determined with PCR method showed the following results: VV: 12 cases (23.5%), VF: 29 cases (56.8%) and FF: 10 cases (19.6%), respectively. There was no significant difference between the treatment responses of the three groups. The event-free survival data were less favorable in the F-allele carriers than in V/V homozygous patients, but without any significancy, and the overall survival curves were almost the same. As for the gene expression profile, 20 patients' biopsy specimens showed germinal center and 31 showed non-germinal center characteristics. Treatment results did not differ from each other in the two groups. Both the event-free and the overall survival data were more favorable in the GC group, however the differences were not significant. Our results contest the predictive value of Fc-gamma-receptor IIIa polymorphism and gene expression profile in diffuse large B-cell lymphoma.

AB - The addition of rituximab to conventional chemotherapy has significantly improved the treatment outcome in diffuse large B-cell lymphoma. However, differences in treatment response and survival data can be observed independently from the International Prognostic Index scores. The current study evaluated the impact of Fc-gamma-receptor IIIa polymorphism and gene expression profile on the response of DLBCL patients to R-CHOP therapy as well as on their survival results. Fifty-one patients were involved, thirty-two females, nineteen males, their median age was 53.1 years. The FCGR3A polymorphism at the 158. amino acid position determined with PCR method showed the following results: VV: 12 cases (23.5%), VF: 29 cases (56.8%) and FF: 10 cases (19.6%), respectively. There was no significant difference between the treatment responses of the three groups. The event-free survival data were less favorable in the F-allele carriers than in V/V homozygous patients, but without any significancy, and the overall survival curves were almost the same. As for the gene expression profile, 20 patients' biopsy specimens showed germinal center and 31 showed non-germinal center characteristics. Treatment results did not differ from each other in the two groups. Both the event-free and the overall survival data were more favorable in the GC group, however the differences were not significant. Our results contest the predictive value of Fc-gamma-receptor IIIa polymorphism and gene expression profile in diffuse large B-cell lymphoma.

KW - Diffuse large B-cell lymphoma

KW - Fc-gamma-receptor IIIa polymorphism

KW - Gene expression profile

KW - Rituximab

KW - Survival

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=84855260118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855260118&partnerID=8YFLogxK

U2 - 10.1007/s12253-011-9414-7

DO - 10.1007/s12253-011-9414-7

M3 - Article

C2 - 21667346

AN - SCOPUS:84855260118

VL - 18

SP - 43

EP - 48

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 1

ER -